Skp2: a dream target in the coming age of cancer therapy

Cell Cycle. 2014;13(5):679-80. doi: 10.4161/cc.27853. Epub 2014 Jan 21.

¹ Department of Molecular and Cellular Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
² Department of Experimental Therapeutics; The University of Texas MD Anderson Cancer Center; Houston, TX USA; The University of Texas Graduate School of Biomedical Sciences at Houston; Houston, TX USA.
³ Department of Molecular and Cellular Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA; The University of Texas Graduate School of Biomedical Sciences at Houston; Houston, TX USA; Graduate Institute of Basic Medical Science; China Medical University; Taichung, Taiwan; Department of Biotechnology; Asia University; Taichung, Taiwan.

No abstract available

Keywords: Skp2 inhibitor; cancer stem cells; cancer therapy; cell cycle arrest; glycolysis; in silico modeling; senescence.

Publication types